Pivotal trials of Astrazeneca's Covid-19 antibody get under way, with hopes that a longer half-life and more convenient dosing will set the project apart.
As antibody tests pile up, Oxford Immunotec is working on an assay to detect T cell responses to the coronavirus.
Analysts see semaglutide helping Novo Nordisk to beat its sales target in obesity, but the company has bigger ambitions for earlier projects.
The German group has come late to antibody testing, but has punchy accuracy data and a possible means of neutralising some of the competition.
IGM's Dan Chen, an expert on coronaviruses, speaks about the value of different ways of trying to treat Covid-19.
The next few months will see data on the cannabinoid Zygel in fragile X syndrome, and a hit – or at least a near miss – will be necessary for more than just approval.
There is a ready market for blood tests that do not involve putting a needle to a vein. Can a new partnership meet the demand?
A strategic change towards Olympus's medical business, and particularly therapeutic procedures, has reignited growth. Next up: acquisitions.
The German start-up must navigate the hazards that have felled other surgical robot developers while simultaneously dealing with a more crowded market.